Literature DB >> 17599438

Late restenosis following sirolimus-eluting stent implantation.

John Cosgrave1, Simon J Corbett, Gloria Melzi, Rade Babic, Giuseppe G L Biondi-Zoccai, Flavio Airoldi, Alaide Chieffo, Giuseppe M Sangiorgi, Matteo Montorfano, Iassen Michev, Mauro Carlino, Antonio Colombo.   

Abstract

Despite encouraging results from randomized trials, concerns exist about long-term results of sirolimus-eluting stent implantation. We sought to determine whether in-stent restenosis occurring >1 year ("late") after sirolimus-eluting stent implantation is a real clinical entity. We analyzed data on all sirolimus-eluting stents implanted in our institution before March 2003. During the study period 928 lesions in 433 patients were treated. Angiographic follow-up was performed in 306 patients (70.6%) with 679 lesions (73.2%). Angiography after 1 year was performed only in symptomatic patients. We considered restenosis "early" if it occurred during the first year and late if after 1 year. Late restenosis required demonstration of a widely patent stent at 6 to 9 months, with repeat angiography after 1 year demonstrating restenosis. Restenosis occurred in 160 lesions overall (23.5%). Of the 31 (4.6%) that were documented after 1 year, 13 were excluded from analysis due to absence of 6- to 9-month angiography; the remaining 18 (2.6%, 1.7 to 4.2) fulfilled our criteria for late restenosis (median time of documentation 607 days, interquartile range 511 to 923). In conclusion, late restenosis is an infrequent but real entity; its existence implies we should not discount the possibility of restenosis as the cause of symptoms that develop >1 year after sirolimus-eluting stent implantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17599438     DOI: 10.1016/j.amjcard.2007.01.070

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Late in-stent restenosis after sirolimus-eluting stent implantation is related to thrombus formation-Insight from a case with IVUS, OCT, and histological findings.

Authors:  Shigenori Ito; Kosuke Nakasuka; Kazuyuki Miyata; Masahiko Inomata; Takayuki Yoshida; Nozomu Tamai; Shin Suzuki; Yoshimasa Murakami; Shugo Suzuki; Koichi Sato
Journal:  J Cardiol Cases       Date:  2012-03-17

2.  Comparison of first- and second-generation drug-eluting stent efficacies for treating left main and/or three-vessel disease: a propensity matched study.

Authors:  Norihiro Kobayashi; Yoshiaki Ito; Keisuke Hirano; Masahiro Yamawaki; Motoharu Araki; Tsuyoshi Sakai; Hideyuki Takimura; Yasunari Sakamoto; Shinsuke Mori; Masakazu Tsutsumi; Takuro Takama; Hiroya Takafuji; Takashi Maruyama; Yohsuke Honda; Takahiro Tokuda; Kenji Makino; Shigemitsu Shirai; Toshiya Muramatsu
Journal:  Heart Vessels       Date:  2016-03-02       Impact factor: 2.037

3.  Serial angiographic and intravascular ultrasound evaluation to interrogate the presence of late "catch-up" phenomenon after Cypher® sirolimus-eluting stent implantation.

Authors:  Daniel Chamié; Alexandre Abizaid; J Ribamar Costa; Fausto Feres; J Fábio Almiro da Silva; Luiz Alberto P Mattos; Rodolfo Staico; Ricardo A Costa; Andréa Abizaid; Luiz Fernando L Tanajura; Amanda G M R Sousa; J Eduardo Sousa
Journal:  Int J Cardiovasc Imaging       Date:  2010-11-17       Impact factor: 2.357

Review 4.  Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V).

Authors:  Imad Sheiban; Gianluca Villata; Mario Bollati; Dario Sillano; Marzia Lotrionte; Giuseppe Biondi-Zoccai
Journal:  Vasc Health Risk Manag       Date:  2008
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.